

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILÎNG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/657,446	09/08/2000	David E. Edgren	ARC 2762C1	1540
7590	08/08/2002		!	
Vandana Date			EXAMINER FUBARA, BLESSING M	
Alza Corporation P O Box 7210	; ;			
Mountain View, CA	A 94043		ART UNIT	PAPER NUMBER
	f ·		1615	<u> </u>
			DATE MAILED: 08/08/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

t	Application No.	Applicant(s)
Advisory Action	09/657,446	EDGREN ET AL.
Advisory Action	Examiner	Art Unit
	Blessing M. Fubara	1615
The MAILING DATE of this communication appe	ears on the cover sheet with the	corresp ndence address
THE REPLY FILED 12 July 2002 FAILS TO PLACE THI Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this application ) a timely filed amendment whic	ation. A proper reply to a the places the application in
PERIOD FOR RE	EPLY [check either a) or b)]	
<ul> <li>a)</li></ul>	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailin S FILED WITHIN TWO MONTHS OF TI	ng date of the final rejection. HE FINAL REJECTION. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offitimely filed, may reduce any earned patent term adjustment. See 37 (	of extension and the corresponding amo the shortened statutory period for reply ce later than three months after the mai	ount of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CF		
2. The proposed amendment(s) will not be entered be	ecause:	
(a) 🛛 they raise new issues that would require furth	er consideration and/or search (	see NOTE below);
(b) They raise the issue of new matter (see Note to	pelow);	
(c)       they are not deemed to place the application i issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the
(d)  they present additional claims without cancel	ing a corresponding number of f	inally rejected claims.
NOTE: The claims originally presented do not re	ecite semipermeable membrane.	
3. Applicant's reply has overcome the following reject	ion(s):	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment
5.⊠ The a) affidavit, b) exhibit, or c) request for application in condition for allowance because: Se		idered but does NOT place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY	to issues which were newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected:		
Claim(s) withdrawn from consideration:		
8. $\square$ The proposed drawing correction filed on is	a) ☐ approved or b) ☐ disapp	roved by the Examiner.
9. $\square$ Note the attached Information Disclosure Statement	nt(s)( PTO-1449)	
10. Other:		THURMAN K. PAGE SUPERVISORY PATENT EXAMIN TECHNOLOGY CENTER 1600

**Advisory Action** 

. . . Ý

Continuation of 5. does NOT place the application in condition for allowance because: The prior art cited, for example, Chen, discloses a controlled release pharmaceutical dosage form that has a dual layer membrane coating a medicament core and the permeability of the membrane are modified by mixing the polymers used in the membrane. One of the membrane in Chen is in contact with the medicament

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600